SB3220: A bill to expand the tropical disease product priority review voucher program to encourage prevention and treatment of coccidioidomycosis.
- 1Introduced (current step)
- 2Passed One Chamber
- 3Passed Both Chambers
- 4Became Law
Here is how to read this bill
Start with the summary
It says what the bill does in plain language. The official text is one tab over.
Check where it is
The status badge says how far it has gotten. The History tab lists every step.
Follow it
We will email you when it moves. You need a free account.
Tell someone who votes on it
Email or call the sponsor, or find your own representatives, from the actions panel.
Bill information
Summary
A bill to expand the tropical disease product priority review voucher program to encourage prevention and treatment of coccidioidomycosis.
Plain-language summary
This bill expands an existing program that gives pharmaceutical companies priority review vouchers for developing drugs treating tropical diseases. It adds coccidioidomycosis, a fungal infection common in the southwestern United States, to the list of diseases covered. Priority review vouchers speed up the FDA's approval process for new medicines, typically from ten months to six months. The bill was recently introduced in Congress and has not yet moved through .
AI-generated summary
What can I do?
It's early in the process — messages to the sponsor and your representatives carry the most weight right now.
Contact Your Representatives
Calling or emailing is the most direct way to weigh in — offices tally constituent contacts.
Find Your RepresentativesShare This Bill
Sharing helps others in your district get informed and involved.
SB3220: A bill to expand the tropical disease product priority review voucher program t…
Upcoming hearings & events
Sponsors
Mark Kelly
Primary SponsorCo-sponsors (4)
Kyrsten Sinema
Markwayne Mullin
John Hickenlooper
Jeff Merkley